Abstract
Etoricoxib is a new, highly selective cyclooxygenase (COX) 2 inhibitor, reported to have an increased cutaneous and systemic safety profile compared to the previous COX-2 inhibitors, including celecoxib, rofecoxib and valdecoxib. To the best of our knowledge, the present case of etoricoxib-induced erythema-multiforme-like eruption is the first reported in the literature.
MeSH terms
-
Aged
-
Arthritis / drug therapy
-
Cyclooxygenase 2 Inhibitors / adverse effects*
-
Drug Eruptions / etiology*
-
Drug Eruptions / pathology
-
Erythema Multiforme / chemically induced*
-
Erythema Multiforme / pathology
-
Etoricoxib
-
Humans
-
Male
-
Pyridines / adverse effects*
-
Skin / pathology
-
Sulfones / adverse effects*
Substances
-
Cyclooxygenase 2 Inhibitors
-
Pyridines
-
Sulfones
-
Etoricoxib